Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cytokine release symptoms rather than syndromes: a call for granular reporting of cytokine-related adverse events in clinical trials.

Annals of oncology : official journal of the European Society for Medical Oncology·2026
Same author

Phase I(b) study evaluating the safety and efficacy of intratumoral agonistic anti-CD40 (selicrelumab) in combination with anti-PD-L1 (atezolizumab) in patients with refractory or relapsed B-cell lymphoma (ITSELF trial).

Immuno-oncology technology·2026
Same author

Breaking the link: IL-6 targeting to uncouple toxicity and efficacy in patients treated with immune checkpoint blockade.

Annals of oncology : official journal of the European Society for Medical Oncology·2025
Same author

Primary central nervous system lymphoma of the spinal cord: A LOC network cohort study.

Revue neurologique·2024
Same author

The ESMO Tumour-Agnostic Classifier and Screener (ETAC-S): a tool for assessing tumour-agnostic potential of molecularly guided therapies and for steering drug development.

Annals of oncology : official journal of the European Society for Medical Oncology·2024
Same author

Immune checkpoint inhibitors for POLE or POLD1 proofreading-deficient metastatic colorectal cancer.

Annals of oncology : official journal of the European Society for Medical Oncology·2024

Related Experiment Video

Updated: Mar 22, 2026

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood
06:07

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Published on: February 5, 2020

6.2K

Biomarkers associated with checkpoint inhibitors.

G Manson1, J Norwood1, A Marabelle2

  • 1Department of Hematology, CHU Rennes, Rennes.

Annals of Oncology : Official Journal of the European Society for Medical Oncology
|April 29, 2016
PubMed
Summary

Checkpoint inhibitors (CPI) show cancer treatment efficacy but cause side effects and varied responses. Biomarkers predicting CPI effectiveness and immune-related adverse events (irAE) are crucial for patient selection.

Keywords:
biomarkerscancercheckpoint inhibitorsimmunotherapy

More Related Videos

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells
09:32

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells

Published on: February 8, 2018

15.7K
Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients
07:42

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients

Published on: February 7, 2021

6.0K

Related Experiment Videos

Last Updated: Mar 22, 2026

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood
06:07

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Published on: February 5, 2020

6.2K
Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells
09:32

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells

Published on: February 8, 2018

15.7K
Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients
07:42

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients

Published on: February 7, 2021

6.0K

Area of Science:

  • Immunology
  • Oncology
  • Pharmacology

Background:

  • Checkpoint inhibitors (CPI), including anti-CTLA4 and anti-PD1/PD-L1 antibodies, are effective cancer treatments.
  • Patient response to CPI varies, with only subgroups benefiting.
  • CPI therapy can lead to severe immune-related adverse events (irAE).

Purpose of the Study:

  • To review key biomarkers associated with CPI efficacy.
  • To identify biomarkers linked to CPI-induced toxicity (irAE).
  • To guide patient selection for CPI therapy.

Main Methods:

  • Literature review of studies on CPI biomarkers.
  • Analysis of pharmacodynamic and clinical benefit markers.
  • Assessment of markers correlating with irAE development.

Main Results:

  • Several biomarkers are associated with CPI efficacy and clinical outcomes.
  • Specific biomarkers correlate with the risk and severity of irAE.
  • Biomarker profiles can differ for efficacy and toxicity.

Conclusions:

  • Biomarkers are essential for predicting CPI response and toxicity.
  • Identifying predictive biomarkers can optimize patient selection for CPI therapy.
  • Further research into biomarkers may improve CPI treatment strategies.